Brief: Aptinyx Completes Enrollment In Phase 2 Study Of Nyx-458 In Cognitive Impairment Associated With Parkinson's Disease And Dementia With Lewy Bodies
25/08/2022 12:33
Aug 25 (Reuters) - Aptinyx Inc APTX.O :
* APTINYX COMPLETES ENROLLMENT IN PHASE 2 STUDY OF NYX-458
IN
COGNITIVE IMPAIRMENT ASSOCIATED WITH PARKINSON’S DISEASE AND
DEMENTIA WITH LEWY BODIES
* APTINYX INC- EXPECTS TO REPORT RESULTS FROM STUDY IN 1Q
2023
Source text for Eikon: ID:nBw8lyz8a
Further company coverage: APTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptinyx
See all newsBrief: Aptinyx Gets Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Aptinyx Inc reports On May 4, Board Deemed It In Best Interests Of Co And Its Stockholders That Co Be Dissolved
Aptinyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aptinyx Inc Reports Quarterly Loss Per Share Of $0.18
Aptinyx Inc expected to post a loss of 19 cents a share - Earnings Preview